Breaking News, Collaborations & Alliances

Abeona Therapeutics, Brammer Bio Form Collaboration

Tie-up to focus on commercial AAV process development, scale up and assay validation

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Abeona Therapeutics has updated its manufacturing strategy and plans for ABO-102, including strategic manufacturing commitments with Brammer Bio for commercial translation. The clinical stage biopharma company also appointed Phillip Maples, vice president of therapeutic development and quality management to oversee all cell-therapy manufacturing and Adam Davis as director to oversee AAV manufacturing. “Our autologous cell and gene therapy programs continue to demonstrate remarkable effects in...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters